OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
41
Results
Show all
Save search
Copy query
Show results for
Unknown
(41)
Publication Date
Release Date
2021
(12)
2022
(6)
2025
(5)
2023
(5)
2024
(3)
2020
(2)
2014
(2)
2013
(2)
2011
(2)
2016
(1)
2015
(1)
Previous
page
1 / 5
You're on page
1
page
2
page
3
page
4
page
5
Next
page
Sort
by:
Relevance
Page size
10
Results of the two incidence screenings in the National Lung Screening Trial.
Not available
S-EPMC4307922
|
biostudies-literature
Cite
Hemorrhagic transformation in acute ischemic stroke: hemorrhagic subtypes and symptomatic intracranial hemorrhage.
Not available
S-EPMC12322388
|
biostudies-literature
Cite
Observation of quantum entanglement with top quarks at the ATLAS detector.
Not available
S-EPMC11410654
|
biostudies-literature
Cite
Surgical treatment of moderate ischemic mitral regurgitation.
Not available
S-EPMC4303577
|
biostudies-literature
Cite
Progression of Tricuspid Regurgitation After Surgery for Ischemic Mitral Regurgitation.
Not available
S-EPMC7953587
|
biostudies-literature
Cite
Risk for non-home discharge following surgery for ischemic mitral valve disease.
Not available
S-EPMC7874266
|
biostudies-literature
Cite
Cost-effectiveness of coronary artery bypass grafting plus mitral valve repair versus coronary artery bypass grafting alone for moderate ischemic mitral regurgitation.
Not available
S-EPMC6960356
|
biostudies-literature
Cite
Two-Year Outcomes of Surgical Treatment of Moderate Ischemic Mitral Regurgitation.
Not available
S-EPMC4908820
|
biostudies-literature
Cite
Effect of Thromboprophylaxis on Clinical Outcomes After COVID-19 Hospitalization.
Not available
S-EPMC10064277
|
biostudies-literature
Cite
The National Lung Screening Trial: overview and study design.
Not available
S-EPMC3009383
|
biostudies-literature
Cite
Previous
page
1 / 5
You're on page
1
page
2
page
3
page
4
page
5
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets